Literature DB >> 8255439

The consortium to establish a registry for Alzheimer's disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease.

J C Morris1, S Edland, C Clark, D Galasko, E Koss, R Mohs, G van Belle, G Fillenbaum, A Heyman.   

Abstract

Reliable information on rate of progression of cognitive impairment in probable Alzheimer's disease (AD) is important for evaluating possible beneficial effects of therapeutic agents and in planning long-term care for patients with this chronic illness. However, wide variability exists in published rates of change for psychometric measures of the dementing process, and there is need for an accurate analysis of large numbers of persons with the disorder studied over long periods. Utilizing the large, well-characterized sample of the Consortium to Establish a Registry for Alzheimer's Disease and employing a least squares regression method to adjust for different levels of impairment and periods of observation, we report rates of change on the Short Blessed Test, Mini-Mental State Examination, Blessed Dementia Scale, Clinical Dementia Rating, and other cognitive measures in 430 patients with probable AD (mean age at entry = 70.9 +/- 8.0 SD years) studied for up to 4 years. We found that rate-of-change determinations are less reliable when the observation period is 1 year or less, that dementia progression may be nonlinear when described by certain measures, and that simple change scores do not accurately characterize the rate of decline. We also found that rate of progression in AD is determined by the severity of cognitive impairment: the less severe the dementia, the slower the rate of decline.

Entities:  

Mesh:

Year:  1993        PMID: 8255439     DOI: 10.1212/wnl.43.12.2457

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  88 in total

1.  3D maps localize caudate nucleus atrophy in 400 Alzheimer's disease, mild cognitive impairment, and healthy elderly subjects.

Authors:  S K Madsen; A J Ho; X Hua; P S Saharan; A W Toga; C R Jack; M W Weiner; P M Thompson
Journal:  Neurobiol Aging       Date:  2010-06-11       Impact factor: 4.673

2.  The Cognitive Change in Women study (CCW): informant ratings of cognitive change but not self-ratings are associated with neuropsychological performance over 3 years.

Authors:  Rebecca Gavett; Julie E Dunn; Anne Stoddard; Brian Harty; Sandra Weintraub
Journal:  Alzheimer Dis Assoc Disord       Date:  2011 Oct-Dec       Impact factor: 2.703

3.  Awareness of memory abilities in community-dwelling older adults with suspected dementia and mild cognitive impairment.

Authors:  Feng Lin; Whitney Wharton; N Maritza Dowling; Michele L Ries; Sterling C Johnson; Cynthia M Carlsson; Sanjay Asthana; Carey E Gleason
Journal:  Dement Geriatr Cogn Disord       Date:  2010-08-12       Impact factor: 2.959

4.  The CERAD Neuropsychologic Battery Total Score and the progression of Alzheimer disease.

Authors:  Heidi C Rossetti; C Munro Cullum; Linda S Hynan; Laura H Lacritz
Journal:  Alzheimer Dis Assoc Disord       Date:  2010 Apr-Jun       Impact factor: 2.703

5.  Assessment of cognitive status in the elderly using telephone interviews.

Authors:  D Debling; M Amelang; P Hasselbach; T Stürmer
Journal:  Z Gerontol Geriatr       Date:  2005-10       Impact factor: 1.281

6.  Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease.

Authors:  I Masse; R Bordet; D Deplanque; A Al Khedr; F Richard; C Libersa; F Pasquier
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-12       Impact factor: 10.154

7.  Type 2 diabetes is negatively associated with Alzheimer's disease neuropathology.

Authors:  Michal Schnaider Beeri; Jeremy M Silverman; Kenneth L Davis; Deborah Marin; Hillel Z Grossman; James Schmeidler; Dushyant P Purohit; Daniel P Perl; Michael Davidson; Richard C Mohs; Vahram Haroutunian
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2005-04       Impact factor: 6.053

8.  Agreement in cognitive and clinical assessments in Alzheimer's disease.

Authors:  Rochelle E Tractenberg; Paul S Aisen
Journal:  Dement Geriatr Cogn Disord       Date:  2009-03-17       Impact factor: 2.959

9.  Differences in brain volume, hippocampal volume, cerebrovascular risk factors, and apolipoprotein E4 among mild cognitive impairment subtypes.

Authors:  Jing He; Sarah Farias; Oliver Martinez; Bruce Reed; Dan Mungas; Charles Decarli
Journal:  Arch Neurol       Date:  2009-11

10.  Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.

Authors:  Aurelia Santoro; Paola Siviero; Nadia Minicuci; Elena Bellavista; Michele Mishto; Fabiola Olivieri; Francesca Marchegiani; Andrea Maria Chiamenti; Luisa Benussi; Roberta Ghidoni; Benedetta Nacmias; Silvia Bagnoli; Andrea Ginestroni; Osvaldo Scarpino; Emidio Feraco; Walter Gianni; Guido Cruciani; Roberto Paganelli; Angelo Di Iorio; Mario Scognamiglio; Luigi Maria Edoardo Grimaldi; Carlo Gabelli; Sandro Sorbi; Giuliano Binetti; Gaetano Crepaldi; Claudio Franceschi
Journal:  CNS Drugs       Date:  2010-02       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.